🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial

RecruitingNAAges 18 Years - anyAllBrigham and Women's Hospital
NCT07787156 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study will test a remote approach to help people who may be at higher risk for pancreatic cancer learn about and decide whether to get genetic testing and a blood test that looks for signs of several cancers (MCED testing). The study is focused on Black, Latino/a, and Medicaid-enrolled individuals who may have had less access to cancer genetics and early detection services. About 80 participants, who reside in Massachusetts, will be assigned by chance to receive either online education alone or online education plus a phone call with a trained educator from the Pancreatic Cancer Action Network (PanCAN). After the education, participants can choose whether or not to have genetic testing and/or MCED testing. The main goal is to learn whether this approach is practical to carry out, acceptable to participants, and delivered as planned. Participants will complete 3 surveys during study

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Aged 50 years or older OR 10 years younger than the earliest PDAC diagnosis in a family member * Current Medicaid enrollment and/or Black and/or Latino/a * Willingness to travel to Dana-Farber Cancer Institute in Boston, MA, for diagnostic testing if MCED screening test indicates possible malignancy * Living in the state of Massachusetts * No prior multi-gene panel genetic testing related to PDAC genetic risk * Internet access to complete study surveys * English speaking * Willing to complete study surveys * At least one first-degree relative with a PDAC diagnosis by participant report OR Any blood relative with a known pathogenic or likely pathogenic variant in a cancer susceptibility gene related to PDAC by participant report (e.g. ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, STK11, or TP53) Exclusion Criteria: * Less than age 50 years or age not within 10 years of the earliest PDAC diagnosis in their family * Cancer diagnosis in the last 3 years (excluding non-melanoma skin cancers) * Currently pregnant * Insurance other than Medicaid or race/ethnicity other than Black or Latino/a * Prior genetic testing related to PDAC genetic risk * Genetic counseling in the last 3 years * Living in a state other than Massachusetts * Language other than English * Three members of the same family already enrolled in the study
💊

What it tests

  • Telephone education session
  • Online educational materials
📍

Where

1 site
Dana-Farber Cancer Institute
Boston, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy